Mirus Bio Corporation

Mirus Bio Corporation is a biopharmaceutical company focused on discovering, developing and commercializing innovative nucleic acid based technologies and products. The company currently markets a range of innovative transfection and labeling reagents worldwide, and is developing therapies based on its proprietary Pathway IV ™ delivery protocol.

Pathway IV ™ is a clinically practical procedure based upon intravenous ("IV") delivery of plasmid DNA ("pDNA") to targeted limb muscle. With blood flow temporarily occluded by a tourniquet, a DNA solution is rapidly injected IV. This elevates the pressure within the occlusion zone, making the blood vessel wall more permeable and allowing the pDNA to migrate into the adjoining muscle cells. Blood flow is then restored to normal within a few minutes, with no adverse affects to the vasculature.

This quick, robust procedure is being used as an enabling platform that will provide first-in-class therapeutic treatments for muscular dystrophy, peripheral ischemia and anemia.

Primary Activity

Material Manufacturer